Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + RGEMOX in Early Relapsed/Refractory DLBCL
NCT06086197Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Complete Response Rate. Started Oct 2023; status: recruiting.
02
Drugs
anlotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06086197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086197.